Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Edward Garon, MD, MS
Conference Coverage
Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?
05/15/2024
Edward Garon, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates...
05/15/2024
Oncology
Edward Garon, MD, MS
Conference Coverage
Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?
05/15/2024
Edward Garon, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates...
05/15/2024
Oncology
Corey Langer, MD
Conference Coverage
The Case Against Antibody Drug Conjugates for Patients With Lung Cancers
05/15/2024
Corey Langer, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.
At the Great Debates and Updates...
05/15/2024
Oncology
Edward Garon, MD, MS
Conference Coverage
Should Pemetrexed Be Continued in Patients Who Receive the KEYNOTE-189 Regimen?
05/14/2024

Featuring Edward Garon, MD, MS

Featuring Edward Garon, MD, MS ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that pemetrexed maintenance therapy should eventually be stopped.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that pemetrexed maintenance therapy should eventually be stopped.
At the Great Debates and Updates...
05/14/2024
Oncology
Corey Langer, MD
Conference Coverage
Advantages to Continuing Pemetrexed as Maintenance Therapy in the KEYNOTE-189 Regimen
05/14/2024
Corey Langer, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates...
05/14/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Use of Liquid Biopsies to Reduce Time to Treatment for Patients With Lung Cancer
05/07/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.
At the Great Debates and Updates...
05/07/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Discussing the Need of Adjuvant Treatment After Neoadjuvant in Early Stage Lung Cancer
05/06/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
At the Great Debates and Updates...
05/06/2024
Oncology
Balazs Halmos, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer
05/03/2024

Featuring Balazs Halmos, MD

Featuring Balazs Halmos, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.
At the Great Debates and Updates...
05/03/2024
Oncology
Rebecca Heist, MD, MPH, Massachusetts General Hospital
Conference Coverage
Targeted Therapies for Patients With Lung Cancer Exhibiting BRAF Mutations or MET Skipping Alterations
05/02/2024

Featuring Rebecca Heist, MD, MPH

Featuring Rebecca Heist, MD, MPH ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates...
05/02/2024
Oncology
Koosha Paydary, MD, MPH, MSc, Rush University Medical Center
Conference Coverage
CTLA-4 Inhibitors for Patients With PD-L1–Negative/PD-L1<1% Lung Cancer
04/29/2024

Featuring Koosha Paydary, MD, MPH, MSc

Featuring Koosha Paydary, MD, MPH, MS...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
At the Great Debates and Updates...
04/29/2024
Oncology

Advertisement

About

Formerly known as Perspectives in Thoracic Oncology, the lung cancer meeting you know and love is getting a makeover. With an updated name to reflect a more pronounced focus on targeted therapies, biomarker testing and precision medicine, year 25 of this educational gathering is getting practical. Personalized Therapies in Thoracic Oncology will go beyond chemotherapy and focus on the best way to treat your patients when traditional methods aren't cutting it. 

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use